Neuroectodermal Tumors  >>  Signifor LAR (pasireotide long acting release)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Signifor LAR (pasireotide long acting release) / Recordati
NCT01590199: Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs

Completed
1
18
Europe
RAD001, Everolimus, SOM230, Paseriotide
Novartis Pharmaceuticals
Neuroendocrine Tumors
09/18
09/18

Download Options